SynektikFRA:A2P +2.38%60 Return-on-Tangible-Equity is 694.34% as of Mar. 2026, which is 3297% above its 10-year median of 20.44. GuruFocus rates FRA:A2P with a GF Score™ of 60/100 and a GF Value™ of €52.56 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 760 Medical Devices & Instruments companies, Synektik ranks better than 94.21% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Synektik's annualized net income for the quarter that ended in Mar. 2026 was €271.5 Mil. Synektik's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €39.1 Mil. Therefore, Synektik's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 694.34%.
The historical rank and industry rank for Synektik's Return-on-Tangible-Equity or its related term are showing as below:
FRA:A2P'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -3.09 Med: 20.44 Max: 241.59
Current: 241.59
During the past 13 years, Synektik's highest Return-on-Tangible-Equity was 241.59%. The lowest was -3.09%. And the median was 20.44%.
FRA:A2P's Return-on-Tangible-Equity is ranked better than 94.21% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.03
vs FRA:A2P: 241.59
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Synektik Return-on-Tangible-Equity Related Terms
Synektik Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Synektik's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:A2P vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Synektik's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synektik Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Synektik's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Synektik's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 694.34% mean?
Synektik (FRA:A2P) has a Return-on-Tangible-Equity of 694.34% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Synektik and its competitors. This is 3297% above median its historical median of 20.44. According to the industry distribution chart, Synektik ranks #44 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 5.8%.
Is Synektik's Return-on-Tangible-Equity too high?
Synektik's current Return-on-Tangible-Equity of 694.34% is 3297% above median its 10-year median of 20.44. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.03. Synektik's value of 694.34% is 17129.3% above this industry median. Based on the distribution chart, Synektik ranks #44 out of 760 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Synektik has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Synektik's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Synektik ranks #44 out of 760 companies for Return-on-Tangible-Equity. This places Synektik in the top 6% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.03. Synektik's value of 694.34% is 17129.3% above this benchmark. While the company's 10-year median is 20.44 vs. the industry median of 4.03, Synektik has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.03, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synektik's current Return-on-Tangible-Equity of 694.34% is 17129.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Synektik and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synektik's current Return-on-Tangible-Equity is 694.34%, which is 3297% above median its own 10-year median of 20.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synektik stock overvalued right now?
Based on GuruFocus' analysis, Synektik (FRA:A2P) is currently considered Significantly Overvalued. The stock's GF Value™ is €52.56, compared to a current price of €88.15 — trading 67.7% above its estimated fair value. The current Return-on-Tangible-Equity is 694.34%, which is 3297% above median its 10-year median of 20.44 and 17129.3% above the Medical Devices & Instruments industry median of 4.03. Synektik's overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Synektik (FRA:A2P), the current Return-on-Tangible-Equity is 694.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synektik (FRA:A2P) Overvalued in 2026?
Based on GuruFocus' analysis, Synektik stock appears to be overvalued.
The current stock price of €88.15 is trading 67.7% above its estimated GF Value™ of €52.56.
GuruFocus considers Synektik to be Significantly Overvalued.
Key valuation signals for FRA:A2P:
Return-on-Tangible-Equity: 694.34% (3297% above median its 10-year median of 20.44)
GF Value™: €52.56 vs. price of €88.15 (67.7% above fair value)
Industry Position: 17129.3% above the Medical Devices & Instruments median (#44 of 760)
No single metric tells the full story. See the FRA:A2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synektik SA is a supplier of innovative products, services and IT solutions for diagnostic imaging and nuclear medicine. It sells medical devices and IT solutions used in radiology and operates research laboratory for diagnostic imaging systems and a service centre for medical equipment. Its operating segments include the sale of medical equipment used in radiology and nuclear medicine and IT solutions, Maintenance services for medical equipment as well as acceptance and specialist tests and Radiopharmaceutical production.
60GF Score
Get the complete analysis for FRA:A2P
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A2P has been successfully added to your 
